{"filings":[{"id":746523,"accession_number":"0001193125-26-248244","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2026-05-29T20:05:20+00:00","items":["5.07"],"status":"ready","headline":"Neumora Therapeutics annual meeting elects directors, ratifies auditor, approves executive compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Paul L. Berns, Matthew Fust, David Piacquad elected with ~126M, ~125M, ~127M votes for, respectively; ~25M broker non-votes.","Ernst & Young ratified as independent auditor for FY 2026 with 157.6M votes for, 53.6K against.","Advisory vote on named executive officer compensation approved: 132.0M for, 420.9K against, 25.0M broker non-votes.","Advisory vote on say-on-pay frequency: majority selected one year; company will hold annual advisory votes on executive compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96542,"accession_number":"0001193125-26-210310","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora Q1 net loss $53.5M, cash $147M; navacaprant data on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $53.5M for Q1 2026, improved from $68.0M in Q1 2025.","Cash and cash equivalents $147.1M as of March 31, 2026; expected to fund operations into Q3 2027.","KOASTAL-2 and -3 fully enrolled with >400 patients each; joint topline readout expected in Q2 2026.","NMRA-511 Phase 1b showed effect in Alzheimer’s agitation; MAD expansion data in H2 2026, Phase 2 planned Q1 2027.","NMRA-898 Phase 1 data in stable schizophrenia expected H2 2026; NMRA-215 preclinical update also in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110544,"accession_number":"0001193125-26-130372","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora FY2025 net loss $236.9M; NMRA-511 positive data; NMRA-215 delayed to Q1 2027; cash to Q3 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $182.5M; FY net loss $236.9M; R&D $176.1M, G&A $60.1M; cash runway into Q3 2027.","NMRA-511: pre-specified analysis (NPI-AA≥4) shows Cohen's d 0.34 on CMAI total, 0.51 on CMAI aggression.","Navacaprant: KOASTAL-2 and -3 fully enrolled (>400 each); topline readout expected Q2 2026.","M4 franchise: NMRA-898 lead; Phase 1 shows ~80-100h half-life, target engagement; MAD study data H2 2026.","NMRA-215: 12-week DIO data supports switch/maintenance; tox finding in 5/142 rats; clinical now Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110543,"accession_number":"0001193125-26-045526","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neumora Therapeutics releases corporate presentation at Guggenheim summit; no material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated February 2026 made available for Guggenheim Emerging Outlook: Biotech Summit.","No financial results, pipeline updates, or guidance changes were provided in the filing.","The filing is a routine Regulation FD disclosure with limited substantive news."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110542,"accession_number":"0001193125-26-009727","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neumora Therapeutics furnishes corporate presentation for J.P. Morgan conference; full content not disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation made available under Item 7.01, not filed for SEC purposes.","Presentation used at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.","No specific pipeline, financial, or operational updates can be extracted from the filing or incomplete exhibit.","Exhibit 99.1 was not fully provided, limiting assessment of material new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110541,"accession_number":"0001193125-26-001472","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NMRA-511 Phase 1b shows clinically meaningful effect in AD agitation; navacaprant readout in Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NMRA-511 Phase 1b: 15.7-point mean CMAI reduction, no somnolence/sedation; plan higher doses and Phase 2/3 in 2026","Navacaprant KOASTAL-2 and -3 joint readout in Q2 2026; enrollment increased up to 25% beyond original target of 332","NMRA-215 Phase 1 for obesity to initiate H1 2026; weight loss data expected around end of 2026","Cash, cash equivalents and marketable securities support operations into Q3 2027; M4 PAM franchise update mid-2026"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127155,"accession_number":"0001193125-25-291352","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"K2HV converts $2.5M loan principal into 2.85M NMRA shares at $0.8774/share","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["K2 HealthVentures converted $2.5M of term-loan principal into 2,849,327 common shares of NMRA at $0.8774/share.","Conversion was exercised under loan agreement dated May 9, 2025, as amended November 4, 2025.","Shares were issued in reliance on Section 4(a)(2) exemption from registration.","Total conversion right under loan agreement remains up to $12.5M; $10M principal remains convertible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127154,"accession_number":"0001193125-25-268046","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora Q3 net loss $56.8M; cash $171.5M; pipeline updates on NMRA-215, M4 PAMs, NMRA-511","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $56.8M for Q3 2025 vs $72.5M in Q3 2024; R&D expense down to $40.5M from $60.6M.","Cash, equivalents, and marketable securities $171.5M; expects to fund operations into 2027.","Drew $40M non-dilutive capital from K2 HealthVentures facility.","NMRA-215 (NLRP3 inhibitor) showed class-leading weight loss in DIO mouse models; Phase 1 expected Q1 2026.","NMRA-511 Phase 1b data in Alzheimer's agitation expected around year-end; navacaprant KOASTAL topline in 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127153,"accession_number":"0001193125-25-250677","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neumora starts Phase 1 study of second M4 PAM, NMRA-898; no convulsions in preclinical","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated Phase 1 SAD/MAD study of NMRA-898, an M4 positive allosteric modulator for schizophrenia and neuropsychiatric disorders.","NMRA-898 is structurally distinct from NMRA-861 (Phase 1 started July 2025); both may offer best-in-class pharmacology.","No convulsions observed in preclinical studies across multiple species, including rabbits.","Neumora expects to provide a comprehensive M4 franchise update by mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127152,"accession_number":"0001193125-25-250656","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neumora reports NMRA-215 preclinical data: up to 19% monotherapy weight loss, 26% with semaglutide","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NMRA-215 showed class-leading 19% weight loss as monotherapy with semaglutide-like induction in DIO mice.","Combination with high-dose semaglutide achieved up to 26% weight loss, best-in-class vs. NLRP3 inhibitors.","Preclinical data support potential as oral, brain-penetrant NLRP3 inhibitor for obesity.","Neumora plans to initiate Phase 1 clinical study for NMRA-215 in Q1 2026.","Additional data to be presented at virtual R&D day on October 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143950,"accession_number":"0000950170-25-103997","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora Q2 net loss $52.7M, cash $217.6M; advances NMRA-861 Phase 1, obesity lead for NMRA-215","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities of $217.6M as of June 30, 2025; expected to fund operations into 2027.","Q2 net loss $52.7M vs $58.7M in Q2 2024; R&D expense fell to $38.7M from $48.6M.","Initiated Phase 1 SAD/MAD study of M4 PAM NMRA-861; data expected Q1 2026.","Prioritized obesity as lead indication for NLRP3 inhibitor NMRA-215; preclinical DIO data expected in 2025, clinical start Q1 2026.","Expects up to six clinical data readouts over next 18 months including navacaprant Phase 3 (1H 2026) and NMRA-511 Phase 1b (end 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162231,"accession_number":"0001193125-25-132307","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neumora Therapeutics stockholders elect directors, approve option repricing and reverse split at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Alaa Halawa (105,795,914 votes for) and Maykin Ho (114,262,481 votes for) as Class II directors.","Ratified Ernst & Young as independent auditor for fiscal 2025 with 135,734,870 votes for.","Approved repricing of certain outstanding stock options under 2020 and 2023 equity plans (101,589,422 for).","Approved reverse stock split at ratio between 1:5 and 1:30, as determined by board (134,256,461 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162230,"accession_number":"0001193125-25-121714","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Neumora receives Nasdaq minimum bid price deficiency notice; has until Nov 10, 2025 to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Neumora on May 14, 2025 that its stock failed to meet the $1.00 minimum bid price requirement.","Company has 180 calendar days, until November 10, 2025, to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not compliant by Nov 10, 2025, Neumora may seek transfer to Nasdaq Capital Market and additional cure period.","Board approved a reverse stock split (1-for-5 to 1-for-30) subject to stockholder vote at Annual Meeting on May 28, 2025.","Neumora intends to monitor bid price and consider options including the reverse split to maintain listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162229,"accession_number":"0000950170-25-069147","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora Q1 net loss $68M, secures $125M venture debt; navacaprant Ph3 data in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $68.0M in Q1 2025, up from $53.7M in Q1 2024; R&D expense $52.2M (incl. $6.3M final Amgen costs).","Cash, equivalents and marketable securities $249.4M as of March 31; plus $20M drawn from K2 HealthVentures extends cash runway into 2027.","Entered $125M venture debt facility with K2 HealthVentures; $20M drawn, additional $20M available by Dec 31, 2025, $85M milestone-based.","Navacaprant KOASTAL-3 topline data expected Q1 2026, KOASTAL-2 Q2 2026; NMRA-511 AD agitation data around end of 2025.","M4 positive allosteric modulator (PAM) program expected to enter clinic in mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162228,"accession_number":"0000950170-25-053303","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K/A","filed_at":"2025-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neumora revises stock option repricing to use closing price on May 28, 2025 annual meeting date","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Originally repriced using Feb 13, 2025 closing price; revised on Apr 7, 2025 to use closing price on scheduled annual meeting date (May 28, 2025).","Repricing applies to eligible options held by board, named executive officers, and other service providers under 2023 and 2020 equity plans.","Reduced exercise price requires stockholder approval; options must be exercised on/after Aug 13, 2026 while service continues.","Except for the closing price date, all other terms of repriced options remain unchanged.","Annual stockholder meeting scheduled for May 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180245,"accession_number":"0000950170-25-030396","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora modifies KOASTAL-2/-3 MDD studies, delays data to 2026; R&D head departs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KOASTAL-2/-3 paused, resume March 2025; topline data from KOASTAL-3 in Q1 2026 and -2 in Q2 2026.","Phase 2 bipolar depression trial for navacaprant discontinued to prioritize KOASTAL program.","Robert Lenz, M.D., Ph.D., head of R&D, leaving company; will serve in advisory role.","Cash, cash equivalents and marketable securities $307.6M as of Dec 31, 2024, funding into mid-2026.","Q4 2024 net loss $58.8M vs $108.7M Q4 2023; full year net loss $243.8M vs $235.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180241,"accession_number":"0001193125-25-031974","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K/A","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neumora Therapeutics appoints Paul Berns as Chairman & CEO, Gosebruch exits","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Henry Gosebruch separates as CEO; receives 12-month base salary, 2025 target bonus, 18-month COBRA, 2024 bonus, and 12-month option exercise period.","Paul L. Berns appointed Chairman & CEO with $700,000 base salary and 60% annual bonus target, effective Feb 14, 2025.","Berns receives option to purchase 2,000,000 shares vesting over 4 years (25% after 1 year, monthly thereafter).","Berns severance: 12 months salary + bonus (non-CIC); 24 months salary + 2x bonus + equity acceleration (CIC-related)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180244,"accession_number":"0001193125-25-026156","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Founder Berns becomes CEO as Gosebruch departs; option repricing approved","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul L. Berns transitions from executive chair to CEO & chairman, effective Feb 14, 2025.","CEO Henry Gosebruch and Chief Commercial Officer Kaya Pai Panandiker leave the company.","Joshua Pinto promoted to president (base $645k, 60% target bonus, $970k signing bonus, 3M option).","Bill Aurora becomes COO & CDO; Michael Milligan becomes CFO; other leadership changes announced.","Board approved option repricing subject to stockholder approval; exercise price set at Feb 13 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180243,"accession_number":"0001193125-25-004999","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neumora Therapeutics presents at J.P. Morgan Healthcare Conference; no specific data disclosed in filing exhibit","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation made available for J.P. Morgan Healthcare Conference on Jan 13, 2025.","Presentation titled \"Redefining Neuroscience Drug Development\" but full content not provided.","No financial or pipeline updates explicitly stated in the 8-K exhibit snippet.","Confidence low due to incomplete exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180242,"accession_number":"0001193125-25-000084","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neumora's Phase 3 KOASTAL-1 study of navacaprant fails primary endpoint in MDD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint MADRS total score change at Week 6: -12.5 for both navacaprant and placebo (p=0.993); no statistical improvement.","Key secondary endpoint SHAPS also missed: -5.8 vs -5.5 (p=0.648).","Pre-specified subgroup analysis showed efficacy signal in females: MADRS LSMD -2.7 (p=0.072); SHAPS LSMD -2.3 (p=0.015).","Navacaprant generally well-tolerated; no serious adverse events; discontinuation 2.1% vs 3.1% for placebo.","Cash balance $342M provides runway into mid-2026; J.P. Morgan Healthcare Conference update planned Jan 14."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197035,"accession_number":"0000950170-24-124563","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora Q3 net loss $72.5M; cash $341.3M; Ph3 MDD data around end-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $341.3M; operations funded into mid-2026.","Q3 R&D expenses $60.6M (vs $41.6M YoY); net loss $72.5M (vs $53.0M).","Phase 3 KOASTAL-1 navacaprant topline data expected around end of 2024.","KOASTAL-2/3 topline data H1 2025; navacaprant Phase 2 bipolar depression data H2 2025.","NMRA-511 Phase 1b AD agitation data H2 2025; M4 PAM IND submission expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213311,"accession_number":"0000950170-24-091205","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora Q2 net loss $58.7M; Phase 3 MDD data on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $371.6M as of June 30, 2024, expected to fund operations into 2026.","R&D expense $48.6M (up from $32.8M); G&A $15.2M (up from $9.3M).","Topline data from KOASTAL-1 Phase 3 study of navacaprant in MDD expected Q4 2024.","Phase 2 trial for navacaprant in bipolar depression initiated; Phase 1b of NMRA-511 in Alzheimer's agitation started.","NMRA-266 study on clinical hold; additional M4 PAM IND submission expected first half 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232492,"accession_number":"0001193125-24-161572","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neumora stockholders elect Gosebruch and Burow as Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Henry O. Gosebruch elected with 88,190,874 votes for, 2,313,739 withheld, and 12,544,469 broker non-votes.","Kristina Burow elected with 87,022,169 votes for, 3,482,444 withheld, and 12,544,469 broker non-votes.","Ratification of Ernst & Young as auditor for FY2024: 102,921,992 for, 123,868 against, 3,222 abstentions.","As of record date April 15, 2024, 159,452,584 shares were outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232491,"accession_number":"0000950170-24-053933","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neumora Q1 net loss $53.7M; navacaprant Phase 3 MDD data on track for Q4 2024; NMRA-266 clinical hold with FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $53.7M in Q1 2024 vs $35.6M in Q1 2023; R&D expense $45.8M, G&A $14.3M.","Cash, cash equivalents and marketable securities of $423.0M; expected to fund operations into 2026.","Topline Phase 3 data from navacaprant KOASTAL-1 in MDD expected Q4 2024; Phase 2 bipolar depression trial to start Q2 2024.","NMRA-511 Phase 1 complete; Phase 1b in Alzheimer's agitation to start Q2 2024 with data in 2025.","FDA placed clinical hold on NMRA-266 Phase 1 study; company working to resolve; additional M4 PAM IND expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232490,"accession_number":"0001193125-24-095472","cik":1885522,"company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neumora's NMRA-266 Phase 1 placed on clinical hold by FDA after rabbit convulsion data","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on NMRA-266 Phase 1 trial due to preclinical convulsions in rabbits.","Approximately 30 participants dosed in study; no convulsions observed in any participant.","Company working with FDA to evaluate resolving the hold; prior guidance on NMRA-266 withdrawn.","NMRA-266 is an M4 muscarinic receptor PAM, part of Neumora's M4 PAM franchise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":339070191.2741935,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}